Toronto, O.N. (Feb. 8, 2021) — Universal PropTech Inc. (TSXV: UPI) is pleased to announce that it is has entered into an agreement with LuminUltra Technologies Ltd. to deploy LuminUltra’s GeneCount® Rapid SARS-CoV-2 surface testing solution for UPI’s current customers which total over 2,000 facilities in Canada today.
The Agreement provides UPI the ability to provide testing services employing LuminUltra’s GeneCount® qPCR tests as a service offering to certain customers that are engaged in providing support services to aviation operators as well as select government and commercial buildings.
“We are very excited to bring LuminUltra’s highly reputable SARS-CoV-2 surface testing solution to our customer base in Canada,” said Chris Hazelton, President and CEO of UPI. “We had committed strategically to expanding our access and investments to key technology and improving our Trusted Advisor status with customers and coupled with our recent announcements in fighting COVID-19 and are well on our way to meeting that commitment to customers and shareholders.”
VCI Controls is now able to recommend air purifier equipment and demonstrate their effectiveness by providing audit support for customers for peace of mind that COVID-19 is not present in their facilities.
LuminUltra provides testing solutions for clinical diagnostics, surface, and wastewater testing. LuminUltra, through its rapid, accurate and portable qPCR tests help safeguard and protect environments by providing verification of disinfection protocols to confirm the absence of the SARS-CoV-2 virus. This helps identify early warning signs which enables the execution of swift response including contact tracing and human testing.
LuminUltra’s GeneCount® qPCR COVID-19 testing solutions are comprised of multiple, flexible components that provide a complete laboratory-grade point-of-need solution. The tests yield results in under two hours that are simple to interpret and possess industry leading accuracy and sensitivity. This gold standard testing method applies the same principles used in human clinical tests. Results are achieved without having to be sent to a lab.
UPI’s wholly owned subsidiary, VCI Controls Inc. will provide these SARS-CoV-2 testing services to its existing client base and certain aviation assets totaling over 2,000 facilities in Canada. Implementation of this technology will help customers with high-traffic facilities to validate environmental infection control processes and better understand the distribution of SARS-CoV-2 in aeronautical facilities in order to allow aviation operators to fly safely, efficiently and privately during these times of heightened public health urgency.
The insight provided by the testing solution will allow the clients to assess the effectiveness of their protocols such as cleaning, contact tracing and individual testing that were implemented to prevent the spread of COVID-19 by providing timely and improved insight into their operations. High-traffic infrastructure facilities such government buildings, educational institutions and airport facilities have an increased obligation to ensure public health safety and LuminUltra’s technology is the solution that will better equip the key decision makers to achieve that objective.
LuminUltra serves some of the most well recognized and reputable companies across the globe including ExxonMobil, EcoLab, and Suez among many others.
“We are pleased to be working with the Universal PropTech team” says Pat Whalen, LuminUltra President & CEO. ”VCI’s experience and long-standing track record is impressive. We’re confident that integrating LuminUltra’s gold-standard qPCR technology into their offerings for government and aviation facilities will ensure a multi-faceted approach to managing COVID-19.”
About Universal PropTech Inc.
Universal PropTech Inc. (TSXV: UPI) is a leading building innovation company, selecting, integrating, deploying, and maintaining PropTech in healthy buildings. As trusted advisors, we provide holistic evidence-driven solutions and services for building developers, owners, and operators in Canada. UPI operates through its wholly owned subsidiary, VCI Controls Inc. (“VCI”), a leading supplier and integrator of PropTech healthy building solutions and services. VCI is an industry leader in the acquisition and deployment of intelligent building technology, including the integration of all building systems utilizing the latest in communications technologies and standards. VCI’s business focuses on digital controls and mechanical services, performance monitoring, and energy efficiency solutions.
With headquarters in Toronto, Universal PropTech Inc. has offices across Canada including, Halifax, Montreal, and Ottawa. For more information, visit www.universalproptech.com.
Founded in 1995, LuminUltra is a biological diagnostic testing company headquartered in Canada with operations in six countries. It is widely recognized globally as a leader in developing tests and reagents for environmental, industrial, and diagnostic monitoring and is a key supplier of COVID-19 clinical testing reagents to the Government of Canada. Customers in over 80 countries trust LuminUltra’s technology, production reliability, and history of customer service excellence to deliver their essential services in a safe-state. At the same time, LuminUltra fosters a culture of innovation and agility and is on an accelerated growth path, acquiring multiple companies in recent years and forming a partnership with the specialized private equity firm XPV Water Partners.
Universal PropTech Inc.
President and Chief Executive Officer